All Stories

  1. Filamentous fungus-produced human monoclonal antibody provides protection against SARS-CoV-2 in hamster and non-human primate models
  2. A pan-orthohantavirus preclinical human lung xenograft mouse model
  3. Presence of procoagulant peripheral blood mononuclear cells in severe COVID-19 patients relate to ventilation perfusion mismatch and precede pulmonary embolism
  4. Human metapneumovirus infection of organoid-derived human bronchial epithelium represents cell tropism and cytopathology as observed in in vivo models
  5. Human conjunctiva organoids to study ocular surface homeostasis and disease
  6. The Safety, Immunogenicity, and Optimal Dosing of an MVA-Based Vaccine Against MERS Coronavirus in Healthy Adults: A Phase 1b, Randomised, Placebo-Controlled, Double-Blind Clinical Trial
  7. Direct comparison of SARS-CoV-2 variant specific neutralizing antibodies in human and hamster sera
  8. Transient Autoreactive PF4 and Antiphospholipid Antibodies in COVID-19 Vaccine Recipients
  9. Fangchinoline inhibits SARS-CoV-2 and MERS-CoV entry
  10. Comparative Pathogenesis of Severe Acute Respiratory Syndrome Coronaviruses
  11. Antigenic evolution of SARS coronavirus 2
  12. The impact of BNT162b2 mRNA vaccine on adaptive and innate immune responses
  13. Comparative Analysis of SARS-CoV-2 Antigenicity across Assays and in Human and Animal Model Sera
  14. SARS-CoV-2 ORF8 accessory protein is a virulence factor
  15. Distinct COVID-19 vaccine combinations result in divergent immune responses
  16. Glycosylated extracellular mucin domains protect against SARS-CoV-2 infection at the respiratory surface
  17. SARS-CoV-2 Omicron entry is type II transmembrane serine protease-mediated in human airway and intestinal organoid models
  18. Filamentous Fungus-Produced Human Monoclonal Antibody Provides SARS-CoV-2 Protection in Hamster and Non-Human Primate Models
  19. Preclinical immunogenicity and protective efficacy of a SARS-CoV-2 RBD-based vaccine produced with the thermophilic filamentous fungal expression system Thermothelomyces heterothallica C1
  20. Correction for Mols et al., “Intestinal Tropism of a Betacoronavirus ( Merbecovirus ) in Nathusius’s Pipistrelle Bat (Pipistrellus nathusii), Its Natural Host”
  21. Detection of double-stranded RNA intermediates of four major SARS-CoV-2 variants in formalin-fixed paraffin-embedded lung tissue of Syrian golden hamsters using monoclonal antibodies
  22. SARS-CoV-2 (B1.1.529) Omicron variant: what has changed in the nose?
  23. ICTV Virus Taxonomy Profile: Coronaviridae 2023
  24. The pro-inflammatory response to influenza A virus infection is fueled by endothelial cells
  25. Mpox Virus Impact on Kidney Organoids and Antiviral Treatment Response
  26. Preclinical immunogenicity and protective efficacy of a SARS-CoV-2 RBD based vaccine produced with the thermophilic filamentous fungal expression system Thermothelomyces heterothallica, C1.
  27. Extended Viral Shedding of MERS-CoV Clade B Virus in Llamas Compared with African Clade C Strain
  28. Intestinal Tropism of a Betacoronavirus ( Merbecovirus ) in Nathusius’s Pipistrelle Bat ( Pipistrellus nathusii ), Its Natural Host
  29. Brief Report: Monkeypox Virus Cross-Neutralizing Antibodies in Clinical Trial Subjects Vaccinated with Modified Vaccinia Virus Ankara Encoding MERS-Coronavirus Spike Protein
  30. Avidity engineering of human heavy-chain-only antibodies mitigates neutralization resistance of SARS-CoV-2 variants
  31. Reduced Seasonal Coronavirus Antibody Responses in Children Following COVID-19 Mitigation Measures, The Netherlands
  32. Antigenic mapping of emerging SARS-CoV-2 omicron variants BM.1.1.1, BQ.1.1, and XBB.1
  33. Low levels of monkeypox virus neutralizing antibodies after MVA-BN vaccination in healthy individuals
  34. Low levels of monkeypox virus neutralizing antibodies after MVA-BN vaccination in healthy individuals
  35. The pro-inflammatory response to influenza A virus infection is fueled by endothelial cells
  36. Outpatient convalescent plasma therapy for high-risk patients with early COVID-19. A randomized placebo-controlled trial
  37. Increased neutralization and IgG epitope identification after MVA-MERS-S booster vaccination against Middle East respiratory syndrome
  38. Pulmonary lesions following inoculation with the SARS-CoV-2 Omicron BA.1 (B.1.1.529) variant in Syrian golden hamsters
  39. Recapitulating infection, thermal sensitivity and antiviral treatment of seasonal coronaviruses in human airway organoids
  40. Persistence of MERS-CoV-spike-specific B cells and antibodies after late third immunization with the MVA-MERS-S vaccine
  41. Protective efficacy of an RBD-based Middle East respiratory syndrome coronavirus (MERS-CoV) particle vaccine in llamas
  42. Antigenic cartography of SARS-CoV-2 reveals that Omicron BA.1 and BA.2 are antigenically distinct
  43. SARS-CoV-2 Omicron variant causes mild pathology in the upper and lower respiratory tract of hamsters
  44. Potency of Fusion-Inhibitory Lipopeptides against SARS-CoV-2 Variants of Concern
  45. An early warning system for emerging SARS-CoV-2 variants
  46. An ACE2-blocking antibody confers broad neutralization and protection against Omicron and other SARS-CoV-2 variants of concern
  47. Methods for fighting emerging pathogens
  48. Defining the risk of SARS-CoV-2 variants on immune protection
  49. SARS-CoV-2 pathogenesis
  50. Pulmonary lesions following inoculation with the SARS-CoV-2 Omicron BA.1 (B.1.1.529) variant in Syrian golden hamsters
  51. The glycosylated extracellular domain of MUC1 protects against SARS-CoV-2 infection at the respiratory surface
  52. Distinct spatial arrangements of ACE2 and TMPRSS2 expression in Syrian hamster lung lobes dictates SARS-CoV-2 infection patterns
  53. Spreading of SARS-CoV-2 from hamsters to humans
  54. Omicron BA.1 and BA.2 are antigenically distinct SARS-CoV-2 variants
  55. An ACE2-blocking antibody confers broad neutralization and protection against Omicron and other SARS-CoV-2 variants
  56. Increased neutralization and IgG epitope identification after MVA-MERS-S booster vaccination against Middle East respiratory syndrome
  57. Modeling Infection and Tropism of Human Parainfluenza Virus Type 3 in Ferrets
  58. Divergent SARS CoV-2 Omicron-reactive T- and B cell responses in COVID-19 vaccine recipients
  59. SARS-CoV-2 Omicron variant causes mild pathology in the upper and lower respiratory tract of Syrian golden hamsters (Mesocricetus auratus)
  60. SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination
  61. SARS-CoV-2 Omicron efficiently infects human airway, but not alveolar epithelium
  62. Middle East respiratory syndrome coronavirus infection in camelids
  63. Divergent SARS CoV-2 Omicron-specific T- and B-cell responses in COVID-19 vaccine recipients
  64. Experimental and field investigations of exposure, replication and transmission of SARS-CoV-2 in pigs in the Netherlands
  65. Interferon-α2 Auto-antibodies in Convalescent Plasma Therapy for COVID-19
  66. Targeted proteomics as a tool to detect SARS-CoV-2 proteins in clinical specimens
  67. Zoonoses Anticipation and Preparedness Initiative, stakeholders conference, February 4 & 5, 2021
  68. The glycosylated extracellular domain of MUC1 protects against SARS-CoV-2 infection at the respiratory surface
  69. Author Correction: The next phase of SARS-CoV-2 surveillance: real-time molecular epidemiology
  70. A CRISPR/Cas9 genetically engineered organoid biobank reveals essential host factors for coronaviruses
  71. The next phase of SARS-CoV-2 surveillance: real-time molecular epidemiology
  72. Seasonal coronavirus-specific B-cells with limited SARS-CoV-2 cross-reactivity dominate the IgG response in severe COVID-19 patients
  73. The Post-Acute Phase of SARS-CoV-2 Infection in Two Macaque Species Is Associated with Signs of Ongoing Virus Replication and Pathology in Pulmonary and Extrapulmonary Tissues
  74. Virological characteristics of SARS-CoV-2 vaccine breakthrough infections in health care workers
  75. Evaluation of a multi-species SARS-CoV-2 surrogate virus neutralization test
  76. Interferon-α Auto-Antibodies in Convalescent Plasma Therapy for COVID-19
  77. Science, not speculation, is essential to determine how SARS-CoV-2 reached humans
  78. Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination
  79. Animal models of SARS-CoV-2 transmission
  80. Advancing lung organoids for COVID-19 research
  81. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection
  82. SARS-CoV-2 neutralizing human antibodies protect against lower respiratory tract disease in a hamster model
  83. SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees
  84. A CRISPR/Cas9 genetically engineered organoid biobank reveals essential host factors for coronaviruses
  85. Human Respiratory Syncytial Virus Subgroup A and B Infections in Nasal, Bronchial, Small-Airway, and Organoid-Derived Respiratory Cultures
  86. Evaluation of a multi-species SARS-CoV-2 surrogate virus neutralization test
  87. The BNT162b2 mRNA vaccine against SARS-CoV-2 reprograms both adaptive and innate immune responses
  88. Human organoid systems reveal in vitro correlates of fitness for SARS-CoV-2 B.1.1.7
  89. High Levels of Neutrophil Extracellular Traps Persist in the Lower Respiratory Tract of Critically Ill Patients With Coronavirus Disease 2019
  90. Human airway cells prevent SARS-CoV-2 multibasic cleavage site cell culture adaptation
  91. Author response: Human airway cells prevent SARS-CoV-2 multibasic cleavage site cell culture adaptation
  92. A Single Subcutaneous or Intranasal Immunization with Adenovirus‐Based SARS‐CoV‐2 Vaccine Induces Robust Humoral and Cellular Immune Responses in Mice
  93. 3D visualization of SARS-CoV-2 infection and receptor distribution in Syrian hamster lung lobes display distinct spatial arrangements
  94. A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies
  95. Review for "A Single Subcutaneous or Intranasal Immunization with Adenovirus‐Based SARS‐CoV‐2 Vaccine Induces Robust Humoral and Cellular Immune Responses in Mice"
  96. Intranasal fusion inhibitory lipopeptide prevents direct-contact SARS-CoV-2 transmission in ferrets
  97. Multimerization- and glycosylation-dependent receptor binding of SARS-CoV-2 spike proteins
  98. Neutrophil extracellular traps persist at high levels in the lower respiratory tract of critically ill COVID-19 patients
  99. Human airway cells prevent SARS-CoV-2 multibasic cleavage site cell culture adaptation
  100. Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19)
  101. Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA SARS 2 S in preclinical vaccination
  102. SARS-CoV-2 entry into human airway organoids is serine protease-mediated and facilitated by the multibasic cleavage site
  103. Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection
  104. Extended Shedding and Enhanced Fitness of the SARS-CoV-2 Variant of Concern B.1.1.7 in Human Organoid Systems
  105. The BNT162b2 mRNA Vaccine Against SARS-CoV-2 Reprograms Both Adaptive and Innate Immune Responses
  106. Susceptibility of rabbits to SARS-CoV-2
  107. Author response: SARS-CoV-2 entry into human airway organoids is serine protease-mediated and facilitated by the multibasic cleavage site
  108. Decision letter: SARS-CoV-2 entry into human airway organoids is serine protease-mediated and facilitated by the multibasic cleavage site
  109. An Organoid‐derived Bronchioalveolar Model for SARS‐CoV‐2 Infection of Human Alveolar‐type II‐like Cells
  110. Development of immunohistochemistry and in situ hybridisation for the detection of SARS-CoV and SARS-CoV-2 in formalin-fixed paraffin-embedded specimens
  111. Effects of Potent Neutralizing Antibodies from Convalescent Plasma in Patients Hospitalized for Severe SARS-CoV-2 Infection.
  112. The Importance of Biobanking for Response to Pandemics Caused by Emerging Viruses: The European Virus Archive As an Observatory of the Global Response to the Zika Virus and COVID-19 Crisis
  113. Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection
  114. Intranasal fusion inhibitory lipopeptide prevents direct contact SARS-CoV-2 transmission in ferrets
  115. Comparison of SARS-CoV-2 infection in two non-human primate species: rhesus and cynomolgus macaques
  116. How the COVID-19 pandemic highlights the necessity of animal research
  117. Isolation of cross-reactive monoclonal antibodies against divergent human coronaviruses that delineate a conserved and vulnerable site on the spike protein
  118. Severe COVID-19 patients display a back boost of seasonal coronavirus-specific antibodies
  119. Animal models for COVID-19
  120. The SARS-CoV-2 multibasic cleavage site facilitates early serine protease-mediated entry into organoid-derived human airway cells
  121. Multimerization- and glycosylation-dependent receptor binding of SARS-CoV-2 spike proteins
  122. Susceptibility of rabbits to SARS-CoV-2
  123. Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands
  124. SARS-CoV-2 neutralizing human antibodies protect against lower respiratory tract disease in a hamster model
  125. How the COVID-19 pandemic highlights the necessity of animal research
  126. Assessing the extent of SARS-CoV-2 circulation through serological studies
  127. SARS-CoV-2 is transmitted via contact and via the air between ferrets
  128. An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment
  129. Convalescent Plasma for COVID-19. A randomized clinical trial
  130. Severe Acute Respiratory Syndrome Coronavirus 2−Specific Antibody Responses in Coronavirus Disease 2019 Patients
  131. Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome
  132. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability
  133. Shedding of infectious virus in hospitalized patients with coronavirus disease-2019 (COVID-19): duration and key determinants
  134. Publisher Correction: A human monoclonal antibody blocking SARS-CoV-2 infection
  135. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability
  136. A human monoclonal antibody blocking SARS-CoV-2 infection
  137. Serologic Detection of Middle East Respiratory Syndrome Coronavirus Functional Antibodies
  138. SARS-CoV-2 productively infects human gut enterocytes
  139. Towards the next phase: evaluation of serological assays for diagnostics and exposure assessment.
  140. SARS-CoV-2 Productively Infects Human Gut Enterocytes
  141. Targeted Proteomics for the Detection of SARS-CoV-2 Proteins
  142. Phenotype of SARS-CoV-2-specific T-cells in COVID-19 patients with acute respiratory distress syndrome
  143. Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model
  144. SARS-CoV-2 is transmitted via contact and via the air between ferrets.
  145. Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Seropositive Camel Handlers in Kenya
  146. Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development
  147. Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial
  148. SARS-CoV-2 specific antibody responses in COVID-19 patients
  149. Comparative Pathogenesis Of COVID-19, MERS And SARS In A Non-Human Primate Model
  150. A human monoclonal antibody blocking SARS-CoV-2 infection
  151. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2
  152. Authors’ response: Plenty of coronaviruses but no SARS-CoV-2
  153. Laboratory readiness and response for novel coronavirus (2019-nCoV) in expert laboratories in 30 EU/EEA countries, January 2020
  154. Severe acute respiratory syndrome-related coronavirus: The species and its viruses – a statement of the Coronavirus Study Group
  155. Statement in support of the scientists, public health professionals, and medical professionals of China combatting COVID-19
  156. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR
  157. Note from the editors: novel coronavirus (2019-nCoV)
  158. Particulate multivalent presentation of the receptor binding domain induces protective immune responses against MERS-CoV
  159. Two-Component Spike Nanoparticle Vaccine Protects Macaques from SARS-CoV-2 Infection
  160. MERS-CoV in Camels but Not Camel Handlers, Sudan, 2015 and 2017
  161. Machine-learning based patient classification using Hepatitis B virus full-length genome quasispecies from Asian and European cohorts
  162. Sensitive and Specific Detection of Low-Level Antibody Responses in Mild Middle East Respiratory Syndrome Coronavirus Infections
  163. Comparison of Serologic Assays for Middle East Respiratory Syndrome Coronavirus
  164. ADAR1: “Editor-in-Chief” of Cytoplasmic Innate Immunity
  165. Failure to detect MERS‐CoV RNA in urine of naturally infected dromedary camels
  166. Species-Specific Colocalization of Middle East Respiratory Syndrome Coronavirus Attachment and Entry Receptors
  167. Lack of Middle East Respiratory Syndrome Coronavirus Transmission in Rabbits
  168. Host Determinants of MERS-CoV Transmission and Pathogenesis
  169. Towards a solution to MERS: protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein
  170. Blocking transmission of Middle East respiratory syndrome coronavirus (MERS-CoV) in llamas by vaccination with a recombinant spike protein
  171. Co-localization of Middle East respiratory syndrome coronavirus (MERS-CoV) and dipeptidyl peptidase-4 in the respiratory tract and lymphoid tissues of pigs and llamas
  172. Chimeric camel/human heavy-chain antibodies protect against MERS-CoV infection
  173. Experimental infection of dromedaries with Middle East respiratory syndrome-Coronavirus is accompanied by massive ciliary loss and depletion of the cell surface receptor dipeptidyl peptidase 4
  174. Middle East respiratory syndrome coronavirus specific antibodies in naturally exposed Israeli llamas, alpacas and camels
  175. Multi-hospital outbreak of a Middle East respiratory syndrome coronavirus deletion variant, Jordan: A molecular, serologic, and epidemiologic investigation
  176. Tissue Distribution of the Mers-Coronavirus Receptor in Bats
  177. Cell Tropism of Middle East Respiratory Syndrome Coronavirus in Experimentally Infected Dromedaries
  178. Identification of sialic acid-binding function for the Middle East respiratory syndrome coronavirus spike glycoprotein
  179. DPP4, the Middle East Respiratory Syndrome Coronavirus Receptor, is Upregulated in Lungs of Smokers and Chronic Obstructive Pulmonary Disease Patients
  180. Phenotypic Differences between Asian and African Lineage Zika Viruses in Human Neural Progenitor Cells
  181. Identification of HCV Resistant Variants against Direct Acting Antivirals in Plasma and Liver of Treatment Naïve Patients
  182. Middle East respiratory syndrome coronavirus experimental transmission using a pig model
  183. MERS-coronavirus: From discovery to intervention
  184. Genetic diversity of hepatitis C virus in Ethiopia
  185. Tissue Distribution of the MERS-Coronavirus Receptor in Bats
  186. Virus genomes reveal factors that spread and sustained the Ebola epidemic
  187. Risk Factors for Primary Middle East Respiratory Syndrome Coronavirus Infection in Camel Workers in Qatar During 2013–2014: A Case-Control Study
  188. Middle East respiratory syndrome coronavirus vaccines: current status and novel approaches
  189. Seroepidemiology of hepatitis B and C virus infections among blood donors in Ethiopia
  190. Livestock Susceptibility to Infection with Middle East Respiratory Syndrome Coronavirus
  191. Respiratory Infection Routes of MERS-CoV in Rabbits
  192. Development of Different Animal Models for Middle East Respiratory Syndrome-Coronavirus (MERS-CoV) Infection
  193. The sample of choice for detecting Middle East respiratory syndrome coronavirus in asymptomatic dromedary camels using real-time reversetranscription polymerase chain reaction
  194. A novel hepatitis B virus subgenotype D10 circulating in Ethiopia
  195. Miscarriage Associated with Zika Virus Infection
  196. Virus genomes reveal the factors that spread and sustained the West African Ebola epidemic.
  197. Naturally occurring recombination in ferret coronaviruses revealed by complete genome characterization
  198. Toward Developing a Preventive MERS-CoV Vaccine—Report from a Workshop Organized by the Saudi Arabia Ministry of Health and the International Vaccine Institute, Riyadh, Saudi Arabia, November 14–15, 2015
  199. MERS-CoV Infection of Alpaca in a Region Where MERS-CoV is Endemic
  200. Deletion Variants of Middle East Respiratory Syndrome Coronavirus from Humans, Jordan, 2015
  201. A poxvirus-based vaccine reduces virus excretion after MERS coronavirus infection in dromedary camels
  202. Hepatitis E Virus (HEV) Genotype 3 Infection of Human Liver Chimeric Mice as a Model for Chronic HEV Infection
  203. Differential Expression of the Middle East Respiratory Syndrome Coronavirus Receptor in the Upper Respiratory Tracts of Humans and Dromedary Camels
  204. Cross host transmission in the emergence of MERS coronavirus
  205. Mers Coronavirus Infection in Dromedary Camels
  206. Ebola virus laboratory response: the three Dutch Mobile laboratories in Liberia and Sierra Leone
  207. Molecular epidemiology and genetic diversity of hepatitis B virus in Ethiopia
  208. An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels
  209. Intrathecal CD4+and CD8+T-cell responses to endogenously synthesized candidate disease-associated human autoantigens in multiple sclerosis patients
  210. Genotypic anomaly in Ebola virus strains circulating in Magazine Wharf area, Freetown, Sierra Leone, 2015
  211. Deployment of Dutch mobile laboratories in the West African Ebola virus response
  212. Follow-up of Contacts of Middle East Respiratory Syndrome Coronavirus–Infected Returning Travelers, the Netherlands, 2014
  213. Novel in vivo and in vitro models of Hepatitis E virus genotype 3 infectivity for chronic human HEV infection
  214. Occupational Exposure to Dromedaries and Risk for MERS-CoV Infection, Qatar, 2013–2014
  215. Detection of Circovirus in Foxes with Meningoencephalitis, United Kingdom, 2009–2013
  216. Asymptomatic Middle East Respiratory Syndrome Coronavirus Infection in Rabbits
  217. Reliable typing of MERS-CoV variants with a small genome fragment
  218. Inflammatory Monocytes Recruited to the Liver within 24 Hours after Virus-Induced Inflammation Resemble Kupffer Cells but Are Functionally Distinct
  219. ATP1A1-Mediated Src Signaling Inhibits Coronavirus Entry into Host Cells
  220. Genome Sequence of Enterovirus D68 and Clinical Disease, Thailand
  221. Identification of Protein Receptors for Coronaviruses by Mass Spectrometry
  222. Mers coronavirus infection of rabbits
  223. High proportion of MERS-CoV shedding dromedaries at slaughterhouse with a potential epidemiological link to human cases, Qatar 2014
  224. Pathogenesis of Middle East respiratory syndrome coronavirus
  225. Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen
  226. Coronavirus Cell Entry Occurs through the Endo-/Lysosomal Pathway in a Proteolysis-Dependent Manner
  227. Travel-related MERS-CoV cases: an assessment of exposures and risk factors in a group of Dutch travellers returning from the Kingdom of Saudi Arabia, May 2014
  228. Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice
  229. Metagenomic Survey for Viruses in Western Arctic Caribou, Alaska, through Iterative Assembly of Taxonomic Units
  230. Exploring the Potential of Next-Generation Sequencing in Detection of Respiratory Viruses
  231. Geographic Distribution of MERS Coronavirus among Dromedary Camels, Africa
  232. Isolation of MERS Coronavirus from a Dromedary Camel, Qatar, 2014
  233. Novel divergent nidovirus in a python with pneumonia
  234. Geographic Distribution of MERS Coronavirus among Dromedary Camels, Africa
  235. New Viruses in Idiopathic Human Diarrhea Cases, the Netherlands
  236. The Pathology and Pathogenesis of Experimental Severe Acute Respiratory Syndrome and Influenza in Animal Models
  237. Middle East respiratory syndrome coronavirus (MERS-CoV) RNA and neutralising antibodies in milk collected according to local customs from dromedary camels, Qatar, April 2014
  238. Membrane ectopeptidases targeted by human coronaviruses
  239. Middle East respiratory syndrome coronavirus (MERS-CoV) infections in two returning travellers in the Netherlands, May 2014
  240. Neutralizing the MERS Coronavirus Threat
  241. MERS: emergence of a novel human coronavirus
  242. Middle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigation
  243. Faculty Opinions recommendation of Middle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigation.
  244. The Novel Human Coronavirus EMC Causes Disease in Macaques but not in Ferrets
  245. Updated Phylogenetic Analysis of Arenaviruses Detected in Boid Snakes
  246. Middle East Respiratory Syndrome coronavirus (MERS-CoV) serology in major livestock species in an affected region in Jordan, June to September 2013
  247. Adenosine Deaminase Acts as a Natural Antagonist for Dipeptidyl Peptidase 4-Mediated Entry of the Middle East Respiratory Syndrome Coronavirus
  248. Comparative efficacy, pharmacokinetic, pharmacodynamic activity, and interferon stimulated gene expression of different interferon formulations in HIV/HCV genotype-1 infected patients
  249. Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study
  250. Inhibition of Middle East Respiratory Syndrome Coronavirus Infection by Anti-CD26 Monoclonal Antibody
  251. Novel Cyclovirus in Human Cerebrospinal Fluid, Malawi, 2010–2011
  252. Middle East Respiratory Syndrome Coronavirus Spike Protein Delivered by Modified Vaccinia Virus Ankara Efficiently Induces Virus-Neutralizing Antibodies
  253. Metagenomic Analysis of the Ferret Fecal Viral Flora
  254. Spiking the MERS-coronavirus receptor
  255. Exosome-mediated transmission of hepatitis C virus between human hepatoma Huh7.5 cells
  256. Identification and Characterization of Two Novel Viruses in Ocular Infections in Reindeer
  257. The Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Does Not Replicate in Syrian Hamsters
  258. The Receptor Binding Domain of the New Middle East Respiratory Syndrome Coronavirus Maps to a 231-Residue Region in the Spike Protein That Efficiently Elicits Neutralizing Antibodies
  259. T-Cell Tropism of Simian Varicella Virus during Primary Infection
  260. MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-  treatment
  261. Identification of Multiple Novel Viruses, Including a Parvovirus and a Hepevirus, in Feces of Red Foxes
  262. Specific serology for emerging human coronaviruses by protein microarray
  263. Detection of novel divergent arenaviruses in boid snakes with inclusion body disease in The Netherlands
  264. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC
  265. Modeling Host Genetic Regulation of Influenza Pathogenesis in the Collaborative Cross
  266. Impact of Soluble CD26 on Treatment Outcome and Hepatitis C Virus-Specific T Cells in Chronic Hepatitis C Virus Genotype 1 Infection
  267. Presence of anti-interferon antibodies is not associated with non-response to peginterferon treatment in chronic hepatitis B
  268. State of Knowledge and Data Gaps of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Humans
  269. Human Coronavirus EMC Does Not Require the SARS-Coronavirus Receptor and Maintains Broad Replicative Capability in Mammalian Cell Lines
  270. Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infections
  271. Genomic Characterization of a Newly Discovered Coronavirus Associated with Acute Respiratory Distress Syndrome in Humans
  272. Performance Evaluation of the New Roche cobas AmpliPrep/cobas TaqMan HCV Test, Version 2.0, for Detection and Quantification of Hepatitis C Virus RNA
  273. Picobirnaviruses in the Human Respiratory Tract
  274. Novel Hepatitis E Virus in Ferrets, the Netherlands
  275. Calicivirus from Novel Recovirus Genogroup in Human Diarrhea, Bangladesh
  276. Impact of Obesity on the Bioavailability of Peginterferon-α2a and Ribavirin and Treatment Outcome for Chronic Hepatitis C Genotype 2 or 3
  277. Expression Quantitative Trait Loci for Extreme Host Response to Influenza A in Pre-Collaborative Cross Mice
  278. Metagenomic Analysis of the Viral Flora of Pine Marten and European Badger Feces
  279. IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C
  280. Enteric Coronavirus in Ferrets, the Netherlands
  281. Twice-weekly pegylated interferon-α-2a and ribavirin results in superior viral kinetics in HIV/hepatitis C virus co-infected patients compared to standard therapy
  282. A Recombinant Influenza A Virus Expressing Domain III of West Nile Virus Induces Protective Immune Responses against Influenza and West Nile Virus
  283. Response Prediction in Chronic Hepatitis C by Assessment of IP-10 and IL28B-Related Single Nucleotide Polymorphisms
  284. Distinct Severe Acute Respiratory Syndrome Coronavirus-Induced Acute Lung Injury Pathways in Two Different Nonhuman Primate Species
  285. Continuous interferon-α2b infusion in combination with ribavirin for chronic hepatitis C in treatment-experienced patients
  286. Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon–ribavirin combination therapy after 4 weeks of treatment
  287. Pharmacodynamics of PEG-IFN-α-2a in HIV/HCV co-infected patients: Implications for treatment outcomes
  288. 2011 IL28B POLYMORPHISM IS SIGNIFICANTLY CORRELATED WITH IFN ANTI-VIRAL EFFECTIVENESS ALREADY ON FIRST DAY OF PEGYLATED INTERFERON-α AND RIBAVIRIN THERAPY OF CHRONIC HCV INFECTION
  289. Nonresponder Patients with Hepatitis C Virus Genotype 2/3 Infection: A Question of Low Systemic Interferon Concentrations?
  290. Exacerbated Innate Host Response to SARS-CoV in Aged Non-Human Primates
  291. Therapeutic response to peg-IFN-alpha-2b and ribavirin in HIV/HCV co-infected African-American and Caucasian patients as a function of HCV viral kinetics and interferon pharmacodynamics
  292. The Application of Genomics to Emerging Zoonotic Viral Diseases
  293. Detection and biological activity of therapeutically induced antibodies to peg-IFN-α-2a in hepatitis C virus infected patients
  294. Interferon response in murine plasmacytoid dendritic cells after SARS coronavirus infection
  295. Early Upregulation of Acute Respiratory Distress Syndrome-Associated Cytokines Promotes Lethal Disease in an Aged-Mouse Model of Severe Acute Respiratory Syndrome Coronavirus Infection
  296. Early Upregulation of Acute Respiratory Distress Syndrome-Associated Cytokines Promotes Lethal Disease in an Aged-Mouse Model of Severe Acute Respiratory Syndrome Coronavirus Infection
  297. SARS
  298. Unraveling the complexities of the interferon response during SARS-CoV infection
  299. Virogenomics: the virus–host interaction revisited
  300. 27 Severe SARS coronavirus infection in aged macaques is associated with reduced expression of anti-inflammatory type-1 interferons
  301. DC-SIGN enhances infection of cells with glycosylated West Nile virus in vitro and virus replication in human dendritic cells induces production of IFN-α and TNF-α
  302. Pathology of Experimental SARS Coronavirus Infection in Cats and Ferrets
  303. Effect of postponed treatment with an anti-tumour necrosis factor (TNF) F(ab')2 fragment on endotoxin-induced cytokine and neutrophil responses in chimpanzees
  304. ALT and viral load decline during PEG-IFN alpha-2b treatment for HBeAg-positive chronic hepatitis B
  305. Complete genome analysis of hepatitis C virus subtypes 6t and 6u
  306. Severe acute respiratory syndrome (SARS) vaccines
  307. Contributors
  308. Modelling of Early Viral Kinetics and Pegylated Interferon-α2b Pharmacokinetics in Patients with HBeAg-Positive Chronic Hepatitis B
  309. HCV-Specific T-Cell Response in Relation to Viral Kinetics and Treatment Outcome (DITTO-HCV Project)
  310. Induction of Regulatory T-Cells and Interleukin-10-Producing Cells in Non-Responders to Pegylated Interferon-α Therapy for Chronic Hepatitis B
  311. Differential antiviral effect of PEG-interferon-??-2b on HIV and HCV in the treatment of HIV/HCV co-infected patients
  312. Characterization of Hepatitis C Virus Deletion Mutants Circulating in Chronically Infected Patients
  313. [520] PREDICTION OF SUSTAINED ALT NORMALIZATION BY VIRAL LOAD DURING PEG-IFN ALPHA-2b TREATMENT FOR HBeAg-POSITIVE CHRONIC HEPATITIS B
  314. P1889 Pharmacokinetic profiles in chronic hepatitis C patients treated with high-dose pegylated interferon
  315. Functional Genomics Highlights Differential Induction of Antiviral Pathways in the Lungs of SARS-CoV–Infected Macaques
  316. The emerging role of ACE2 in physiology and disease
  317. Mycophenolic Acid Inhibits Hepatitis C Virus Replication and Acts in Synergy With Cyclosporin A and Interferon-α
  318. Interferon (IFN)–γ–Inducible Protein–10: Association with Histological Results, Viral Kinetics, and Outcome during Treatment with Pegylated IFN‐α2a and Ribavirin for Chronic Hepatitis C Virus Infection
  319. Novel in-vitro and in vivo models
  320. Genotyping Hepatitis C Viruses from Southeast Asia by a Novel Line Probe Assay That Simultaneously Detects Core and 5' Untranslated Regions
  321. Interferon-γ and interleukin-4 downregulate expression of the SARS coronavirus receptor ACE2 in Vero E6 cells
  322. Coronaviruses and their therapy
  323. Identification of a Naturally Occurring Recombinant Genotype 2/6 Hepatitis C Virus
  324. Nonhuman Primate Models for SARS
  325. Antibodies Neutralizing Peginterferon Alfa during Retreatment of Hepatitis C
  326. Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: Relation to treatment response
  327. IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection
  328. Virus Specific Immune Responses after Human Neoadjuvant Adenovirus-mediated Suicide Gene Therapy for Prostate Cancer
  329. Immunisation with virion-loaded plasmacytoid or myeloid dendritic cells induces primary Th-1 immune responses
  330. Monitoring intrahepatic CD8+ T cells by fine-needle aspiration cytology in chronic hepatitis C infection
  331. Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets
  332. Host-dependent type 1 cytokine responses driven by inactivated viruses may fail to default in the absence of IL-12 or IFN- / 
  333. Pegylated interferon-α protects type 1 pneumocytes against SARS coronavirus infection in macaques
  334. 848 Neoadjuvant prostate cancer gene therapy: Clinical and pre-clinical results
  335. 494 Analysis of peripheral HCV-specific T cell responses associated with rapid viral decline during PEG-interferon-alfa-2A and ribavirin therapy (DITTO-HCV project)
  336. Pretreatment Intrahepatic CD8 + Cell Count Correlates with Virological Response to Antiviral Therapy in Chronic Hepatitis C Virus Infection
  337. SARS virus infection of cats and ferrets
  338. Prostate cancer gene therapy: Preliminary clinical and pre-clinical results
  339. Prostate cancer gene therapy: Preliminary clinical and pre-clinical results
  340. The glycosylation status of the murine hepatitis coronavirus M protein affects the interferogenic capacity of the virus in vitro and its ability to replicate in the liver but not the brain
  341. A replicon-based bioassay for the measurement of interferons in patients with chronic hepatitis C
  342. Comparative study of different methods to genotype hepatitis C virus type 6 variants
  343. Pretreatment intrahepatic CD8+ cell number correlates with virological response to antiviral therapy in chronic hepatitis C
  344. Molecular epidemiology of gibbon hepatitis B virus transmission
  345. Rat testicular germ & sertoli cells release different types of bioactive TGF-β in vitro
  346. Protective Antiviral Immune Responses to Pseudorabies Virus Induced by DNA Vaccination Using Dimethyldioctadecylammonium Bromide as an Adjuvant
  347. DITTO-HCV early viral kinetics report - novel decline patterns in gen 1 but not gen 2–3 patients treated with PEG-interferon-alfa-2a and ribavirin
  348. Long-term HBV kinetics classification during treatment with adefovir dipivoxil
  349. Identification and characterisation of adenovirus specific T cell responses in prostate cancer patients receiving ADV5-RSV-TK gene therapy
  350. Adverse effects of feline IL-12 during DNA vaccination against feline infectious peritonitis virus
  351. Corrigendum to “A DNA vaccine coding for glycoprotein B of pseudorabies virus induces cell-mediated immunity in pigs and reduces virus excretion early after infection” [Vet. Immunol. Immunopathol. 74 (2000) 121–136]
  352. Foreign-body reaction to dermal sheep collagen in interferon-?-receptor knock-out mice
  353. A DNA vaccine coding for glycoprotein B of pseudorabies virus induces cell-mediated immunity in pigs and reduces virus excretion early after infection
  354. Cytokine mRNAs in liver biopsy samples predict complete virus eradication with interferon-α ribavirin treatment in chronic hepatitis
  355. Vaccination of pigs against pseudorabies virus with plasmid DNA encoding glycoprotein D
  356. Effect of vaccination route and composition of DNA vaccine on the induction of protective immunity against pseudorabies infection in pigs
  357. Mice Lacking IL-12 Develop Polarized Th1 Cells During Viral Infection
  358. Persistence and Evolution of Feline Coronavirus in a Closed Cat-Breeding Colony
  359. Neutrophil induced T-cell apoptosis during a viral infection
  360. Neutrophil induced T-cell apoptosis during a viral infection
  361. Virus-induced type-1 cytokine response in IL-12 deficient mice
  362. Vaccination of pigs with plasmid DNA coding for glycoproteins of pseudorables virus provides protection against challenge infection with pseudorables virus
  363. Transforming growth factor beta production during rat cytomegalovirus infection.
  364. Apoptosis and T-cell depletion during feline infectious peritonitis.
  365. Tumour necrosis factor-  production during cytomegalovirus infection in immunosuppressed rats
  366. Differential effects of anti-tumor necrosis factor monoclonal antibodies on systemic inflammatory responses in experimental endotoxemia in chimpanzees
  367. Differential effects of anti-tumor necrosis factor monoclonal antibodies on systemic inflammatory responses in experimental endotoxemia in chimpanzees
  368. Suppression of rat cytomegalovirus replication by antibodies against gamma interferon.
  369. Tumor necrosis factor alpha promotes replication and pathogenicity of rat cytomegalovirus.
  370. Tumor necrosis factor α levels in cats experimentally infected with feline immunodeficiency virus: effects of immunization and feline leukemia virus infection
  371. Pneumococcal conjugate vaccines
  372. Tumour necrosis factor- , interferon-  and interferon-beta exert antiviral activity in nervous tissue cells
  373. Protection of Rats against Pseudorabies Virus Infection by  -Interferon